Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Journal of Psychopharmacology (Oxford, England)
|
November 15, 2017
Combination therapy for obesity
John Ph Wilding
European Cardiology
|
June 24, 2026
The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
Alex E Henney, John Ph Wilding
Future Cardiology
|
January 10, 2020
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes
Dalal Y Al-Bazz, John Ph Wilding
Expert Opinion on Pharmacotherapy
|
July 20, 2021
Dapagliflozin for the treatment of type 2 diabetes mellitus - an update
Martha K Nicholson, Randa Ghazal Asswad, John Ph Wilding
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
October 30, 2025
Tirzepatide and the NHS: are we creating a two-tier obesity treatment system?
Laurence J Dobbie, Mariam Molokhia, John Ph Wilding, et al.
Nutrition & Metabolism
|
June 16, 2007
Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study
Sameer Fatani, Lucy C Pickavance, Claire J Sadler, et al.
Sleep Science (Sao Paulo, Brazil)
|
October 21, 2015
Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment
Ian W Seetho, Adela Ramírez-Torres, Amaya Albalat, et al.
Metabolites
|
June 25, 2025
Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study)
Werd Al-Najim, Babak Dehestani, Ahmed W Al-Humadi, et al.
BMJ Open
|
July 21, 2021
A <u>r</u>andomis<u>e</u>d, controlled, double blind <u>s</u>tudy to assess mechan<u>i</u>stic effects of combination therapy of dapag<u>li</u>flozin with <u>e</u>xenatide QW versus dapagliflozin alone i<u>n</u> obese patients with <u>t</u>ype 2 diabetes mellitus (RESILIENT): study protocol
Emily Brown, Moon M Wilton, Victoria S Sprung, et al.
BMJ Open
|
July 24, 2020
Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI)
Victoria S Sprung, Graham J Kemp, John Ph Wilding, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Journal of Psychopharmacology (Oxford, England)
|
November 15, 2017
Combination therapy for obesity
John Ph Wilding
European Cardiology
|
June 24, 2026
The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
Alex E Henney, John Ph Wilding
Future Cardiology
|
January 10, 2020
Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes
Dalal Y Al-Bazz, John Ph Wilding
Expert Opinion on Pharmacotherapy
|
July 20, 2021
Dapagliflozin for the treatment of type 2 diabetes mellitus - an update
Martha K Nicholson, Randa Ghazal Asswad, John Ph Wilding
The British Journal of General Practice : the Journal of the Royal College of General Practitioners
|
October 30, 2025
Tirzepatide and the NHS: are we creating a two-tier obesity treatment system?
Laurence J Dobbie, Mariam Molokhia, John Ph Wilding, et al.
Nutrition & Metabolism
|
June 16, 2007
Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study
Sameer Fatani, Lucy C Pickavance, Claire J Sadler, et al.
Sleep Science (Sao Paulo, Brazil)
|
October 21, 2015
Urinary proteomic profiling in severe obesity and obstructive sleep apnoea with CPAP treatment
Ian W Seetho, Adela Ramírez-Torres, Amaya Albalat, et al.
Metabolites
|
June 25, 2025
Outcomes of Different Lifestyle Approaches in a Multicentre, Open-Label, Parallel-Group, Randomised Controlled Trial of the Effectiveness of Integrating a Pragmatic Pathway for Prescribing Liraglutide 3.0 mg in Weight Management Services (STRIVE Study)
Werd Al-Najim, Babak Dehestani, Ahmed W Al-Humadi, et al.
BMJ Open
|
July 21, 2021
A <u>r</u>andomis<u>e</u>d, controlled, double blind <u>s</u>tudy to assess mechan<u>i</u>stic effects of combination therapy of dapag<u>li</u>flozin with <u>e</u>xenatide QW versus dapagliflozin alone i<u>n</u> obese patients with <u>t</u>ype 2 diabetes mellitus (RESILIENT): study protocol
Emily Brown, Moon M Wilton, Victoria S Sprung, et al.
BMJ Open
|
July 24, 2020
Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI)
Victoria S Sprung, Graham J Kemp, John Ph Wilding, et al.
Page
of 2